This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderson, L. M. Articles by Rice, J. M. Search for Related Content PubMed PubMed Citation Articles by Anderson, L. M. Articles by Rice, J. M.

Evaluation of the Transplacental Tumorigenicity of the Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone in Mice¹

Laboratory of Comparative Carcinogenesis, Division of Cancer Etiology, National Cancer Institute, Frederick, Maryland 21701 [L. M. A., D. E. D., L. F. D., J. M. R.]; Pathology Associates, Inc., Ijamsville, Maryland 21754 [R. M. K.]; and Naylor Dana Institute for Disease Prevention, American Health Foundation, Valhalla, New York 10595 [S. S. H., S. A., D. H.]

The transplacental tumorigenicity of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) was assessed in three strains of mice: A/J; C3H/He x C57BL/6 F₁ (hereafter called C3B6F₁); and Swiss outbred [Cr:NIH(S)]. NNK (100 mg/kg) was administered i.p. on Days 14, 16, and 18 of gestation to A/J and C3H/He mice and on Days 15, 17, and 19 of gestation to the Swiss mice. The effects of postnatal treatment with tumor-promoting agents, including 0.05% sodium barbital in the drinking water until death or a single dose of Aroclor 1254 (a mixture of polychlorinated biphenyls, PCB) given on Postnatal Day 8 or 56, were also examined. Progeny were sacrificed at age 24 wk (A/J) or 72 wk (C3B6F₁ and Swiss). Significant incidences of tumors occurred in the lungs of strain A/J progeny and in the livers of male C3B6F₁ and Swiss progeny. Lung tumor incidence was 8 of 34 (24%) in the female offspring of the A/J mice treated with NNK, compared with 1 of 39 (3%) in controls (P < 0.05). A 2-fold difference in lung tumor incidence in male offspring of NNK-treated (4 of 23, 13%) versus control (3 of 48, 6%) A/J mice was not of statistical significance. However, the incidence of lung tumors in NNK-exposed progeny A/J mice in both sexes combined (12 of 66, 18%) was also significantly greater than in controls (4 of 87, 5%). The incidence of liver tumors in the male C3B6F₁ mice exposed transplacentally to NNK was 12 of 30 (40%) compared to 8 of 46 (17%) in controls (P < 0.05). No effects of postnatal sodium barbital or PCB were observed on transplacental NNK tumorigenicity in C3B6F₁ mice. The combined incidence of liver carcinoma in male mice in all NNK-treated groups (13 of 141, 9%) was significantly greater (P < 0.05) than in controls (5 of 144, 3%). In male Swiss mice exposed transplacentally to NNK, the incidence of liver tumors was 3 of 57 (5%) compared to 0 of 35 controls, and postnatal treatment with PCB on Day 56 caused a significant increase (5 of 26, 19%) (P < 0.05) in the incidence of NNK-induced liver tumors. The combined incidence of liver tumors in the male offspring of the Swiss mice treated with NNK, with or without PCB, was 8 of 83 (10%) which was significantly greater (P < 0.05) than in controls (0 of 66). The mothers in all NNK-treated groups of all three strains developed lung tumors in high incidence and multiplicity, and C3H mothers also presented a significant number of liver tumors. Taken together, the results of this study demonstrate that NNK is a transplacental tumorigen in the mouse, with activity that is relatively weak compared with the adult and is demonstrable only in fetal target organs of high sensitivity.

¹ Supported in part by Grant CA-29580 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at NCI-FCRF, Building 538, Room 205E, Frederick, MD 21701.

Received 12/10/88. Revised 4/ 3/89. Accepted 4/13/89.

This article has been cited by other articles:

				D. J. Castro, W. M. Baird, C. B. Pereira, J. Giovanini, C. V. Lohr, K. A. Fischer, Z. Yu, F. J. Gonzalez, S. K. Krueger, and D. E. Williams Fetal Mouse Cyp1b1 and Transplacental Carcinogenesis from Maternal Exposure to Dibenzo(a,l)pyrene Cancer Prevention Research, July 1, 2008; 1(2): 128 - 134. [Abstract] [Full Text] [PDF]

				Y. Weng, C. Fang, R. J. Turesky, M. Behr, L. S. Kaminsky, and X. Ding Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome P450 Reductase-Null Mice Cancer Res., August 15, 2007; 67(16): 7825 - 7832. [Abstract] [Full Text] [PDF]

				Z. Yu, C. V. Loehr, K. A. Fischer, M. A. Louderback, S. K. Krueger, R. H. Dashwood, N. I. Kerkvliet, C. B. Pereira, J. E. Jennings-Gee, S. T. Dance, et al. In utero Exposure of Mice to Dibenzo[a,l]Pyrene Produces Lymphoma in the Offspring: Role of the Aryl Hydrocarbon Receptor Cancer Res., January 15, 2006; 66(2): 755 - 762. [Abstract] [Full Text] [PDF]

				L. Zhang, D. L. Weddle, P. E. Thomas, B. Zheng, A. Castonguay, H. M. Schuller, and M. S. Miller Low Levels of Expression of Cytochromes P-450 in Normal and Cancerous Fetal Pancreatic Tissues of Hamsters Treated with NNK and/or Ethanol Toxicol. Sci., August 1, 2000; 56(2): 313 - 323. [Abstract] [Full Text] [PDF]

				G. M. Lackmann, U. Salzberger, U. Tollner, M. Chen, S. G. Carmella, and S. S. Hecht Metabolites of a Tobacco-Specific Carcinogen in Urine From Newborns J Natl Cancer Inst, March 3, 1999; 91(5): 459 - 465. [Abstract] [Full Text] [PDF]

				L. M. Winn, P. M. Kim, and P. G. Wells Investigation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone for In Vivo and In Vitro Murine Embryopathy and Embryonic ras Mutations J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1128 - 1135. [Abstract] [Full Text]